Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 15 studies | 34% ± 10% | |
microglial cell | 12 studies | 36% ± 15% | |
macrophage | 11 studies | 35% ± 14% | |
oligodendrocyte | 10 studies | 32% ± 16% | |
oligodendrocyte precursor cell | 10 studies | 30% ± 16% | |
fibroblast | 10 studies | 28% ± 9% | |
adipocyte | 9 studies | 48% ± 16% | |
GABAergic neuron | 8 studies | 47% ± 23% | |
glutamatergic neuron | 8 studies | 52% ± 26% | |
astrocyte | 8 studies | 38% ± 18% | |
epithelial cell | 6 studies | 28% ± 15% | |
dendritic cell | 6 studies | 24% ± 7% | |
mast cell | 6 studies | 22% ± 6% | |
pericyte | 6 studies | 27% ± 7% | |
myeloid cell | 6 studies | 31% ± 13% | |
endothelial cell of lymphatic vessel | 6 studies | 29% ± 8% | |
smooth muscle cell | 6 studies | 23% ± 7% | |
neuron | 5 studies | 44% ± 18% | |
interneuron | 5 studies | 53% ± 25% | |
B cell | 5 studies | 26% ± 9% | |
cardiac muscle cell | 5 studies | 34% ± 8% | |
T cell | 5 studies | 26% ± 6% | |
monocyte | 5 studies | 36% ± 11% | |
type I pneumocyte | 5 studies | 27% ± 5% | |
type II pneumocyte | 5 studies | 25% ± 5% | |
granule cell | 4 studies | 28% ± 9% | |
ciliated cell | 4 studies | 25% ± 6% | |
retinal rod cell | 4 studies | 26% ± 6% | |
club cell | 4 studies | 26% ± 8% | |
natural killer cell | 4 studies | 24% ± 7% | |
CD4-positive, alpha-beta T cell | 3 studies | 19% ± 2% | |
GABAergic amacrine cell | 3 studies | 22% ± 4% | |
Mueller cell | 3 studies | 25% ± 8% | |
amacrine cell | 3 studies | 24% ± 5% | |
glycinergic amacrine cell | 3 studies | 24% ± 4% | |
retina horizontal cell | 3 studies | 27% ± 6% | |
retinal cone cell | 3 studies | 30% ± 6% | |
endothelial cell of vascular tree | 3 studies | 28% ± 10% | |
hepatocyte | 3 studies | 41% ± 25% | |
alveolar macrophage | 3 studies | 44% ± 9% | |
respiratory goblet cell | 3 studies | 31% ± 11% | |
lymphocyte | 3 studies | 28% ± 9% | |
basal cell | 3 studies | 34% ± 19% | |
mucus secreting cell | 3 studies | 23% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1678.56 | 1445 / 1445 | 100% | 20.14 | 183 / 183 |
lung | 100% | 2023.87 | 578 / 578 | 100% | 15.50 | 1153 / 1155 |
ovary | 100% | 1962.64 | 180 / 180 | 100% | 13.00 | 428 / 430 |
brain | 99% | 1525.15 | 2622 / 2642 | 100% | 16.64 | 705 / 705 |
breast | 100% | 2066.91 | 459 / 459 | 99% | 17.89 | 1109 / 1118 |
intestine | 100% | 1639.33 | 966 / 966 | 99% | 12.30 | 521 / 527 |
thymus | 100% | 1882.72 | 653 / 653 | 99% | 15.29 | 598 / 605 |
stomach | 100% | 1203.55 | 359 / 359 | 99% | 13.31 | 282 / 286 |
pancreas | 100% | 862.00 | 327 / 328 | 99% | 13.37 | 176 / 178 |
bladder | 100% | 2049.90 | 21 / 21 | 98% | 11.86 | 496 / 504 |
prostate | 100% | 1771.49 | 245 / 245 | 98% | 13.07 | 494 / 502 |
uterus | 100% | 1969.06 | 170 / 170 | 98% | 12.20 | 450 / 459 |
kidney | 100% | 1300.67 | 89 / 89 | 98% | 15.48 | 879 / 901 |
skin | 100% | 2479.40 | 1809 / 1809 | 97% | 17.06 | 457 / 472 |
adrenal gland | 100% | 1614.44 | 258 / 258 | 90% | 10.20 | 208 / 230 |
liver | 100% | 969.79 | 226 / 226 | 83% | 6.60 | 339 / 406 |
adipose | 100% | 2020.61 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1908.59 | 1335 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 1574.23 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2171.82 | 241 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 2173.25 | 913 / 929 | 0% | 0 | 0 / 0 |
heart | 97% | 1099.72 | 833 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 10.95 | 28 / 29 |
tonsil | 0% | 0 | 0 / 0 | 96% | 13.04 | 43 / 45 |
eye | 0% | 0 | 0 / 0 | 81% | 6.60 | 65 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0030511 | Biological process | positive regulation of transforming growth factor beta receptor signaling pathway |
GO_0016567 | Biological process | protein ubiquitination |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0031398 | Biological process | positive regulation of protein ubiquitination |
GO_0070911 | Biological process | global genome nucleotide-excision repair |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0007389 | Biological process | pattern specification process |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0016605 | Cellular component | PML body |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0032184 | Molecular function | SUMO polymer binding |
GO_0046332 | Molecular function | SMAD binding |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
Gene name | RNF111 |
Protein name | Ring finger protein 111 Alternative protein RNF111 E3 ubiquitin-protein ligase Arkadia (EC 2.3.2.27) (RING finger protein 111) (hRNF111) (RING-type E3 ubiquitin transferase Arkadia) |
Synonyms | |
Description | FUNCTION: E3 ubiquitin-protein ligase . Required for mesoderm patterning during embryonic development (By similarity). Acts as an enhancer of the transcriptional responses of the SMAD2/SMAD3 effectors, which are activated downstream of BMP . Acts by mediating ubiquitination and degradation of SMAD inhibitors such as SMAD7, inducing their proteasomal degradation and thereby enhancing the transcriptional activity of TGF-beta and BMP . In addition to enhance transcription of SMAD2/SMAD3 effectors, also regulates their turnover by mediating their ubiquitination and subsequent degradation, coupling their activation with degradation, thereby ensuring that only effectors 'in use' are degraded (By similarity). Activates SMAD3/SMAD4-dependent transcription by triggering signal-induced degradation of SNON isoform of SKIL . Associates with UBE2D2 as an E2 enzyme . Specifically binds polysumoylated chains via SUMO interaction motifs (SIMs) and mediates ubiquitination of sumoylated substrates . Catalyzes 'Lys-63'-linked ubiquitination of sumoylated XPC in response to UV irradiation, promoting nucleotide excision repair . Mediates ubiquitination and degradation of sumoylated PML (By similarity). The regulation of the BMP-SMAD signaling is however independent of sumoylation and is not dependent of SUMO interaction motifs (SIMs) (By similarity). . |
Accessions | Q6ZNA4 ENST00000559160.1 ENST00000557998.5 [Q6ZNA4-1] ENST00000348370.9 [Q6ZNA4-2] H0YKK5 L0R5C6 ENST00000561186.5 [Q6ZNA4-3] ENST00000559209.5 [Q6ZNA4-4] ENST00000559757.1 ENST00000559592.1 H0YLK9 H0YKS2 |